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TO THE EDITOR
Acute myeloid leukemia (AML) has an incidence of 2/100 000 inhabitants. Familial AML is a rare syndrome and its occurrence in two kindreds is less than 4/10 9 inhabitants. A few pedigrees have been reported, underlying potential but as yet unidentified genetic mechanisms predisposing to AML. On the other hand, the autoimmune polyendocrine syndrome (APS) is defined as the occurrence of several autoimmune diseases of the endocrine system in the same patient. 1 Two types of APS have been described. The autoimmune polyendocrine syndrome type II (APS II) syndrome most frequently associates with autoimmune thyroid disorders (AITD), Addison's disease and Type I diabetes. In this syndrome, AITD encompasses a spectrum of thyroid disorders, including Hashimoto's disease and Graves' disease. For most of the APS II component disorders, the incidence of multiple affected members in a given family is common. Such autoimmune events may be subclinical and detected only by serological tests. 'Nonclassic' APS II is a group of autoimmune disorders with neither Addison's disease nor APS I syndrome. Such autoimmune disorders may include hypogonadism, vitiligo, alopecia, pernicious anemia, myasthenia gravis and a number of less common disorders. Major histocompatibility complex genes confer susceptibility to the development of autoimmune disorders. Familial APS have seldom been reported previously. The association of AML with APSII has not been described, although AITD are often associated with AML. We present a man and his daughter with a syndrome of apparently autosomal adultonset APSII and AML (Figure 1) .
A 40-year-old man was first admitted to the hospital in 1978. A transient ischemic attack, hypercholesterolemia, high blood pressure and polyarthritis of unknown cause were noticed in his medical history. He had developed an AML 2 with 97.6% blasts plus promyelocytes in the bone marrow. Cytogenetics were unsuccessful. He achieved a complete remission after induction chemo-therapy (Daunorubicine, Vincristine, Cytarabine). He then received two courses of consolidation (Daunorubicine, Vincristine, Cytarabine) and 13 courses of maintenance (MethylGAG, Cyclophosphamide, Cytarabine) chemotherapy. The treatment was completed 2 years after diagnosis by two final courses of chemotherapy (Daunorubicine, Vincristine, Mercaptopurine). After chemotherapy, he developed impotence because of testicular failure with normal adrenal function tests. In April 1999, myasthenia gravis was diagnosed by an EMG decrement of 30%, a positive prostigmine test and antibodies against the acetylcholine receptor at 7.36 mmol/l. The myasthenia syndrome was associated with myositis (rise of CPK to 891 U/l). Furthermore, antibodies against skeletal muscle were positive with a titration at 1/10. In July 1999, he developed an autoimmune thyroiditis with an euthyroid homogeneous goiter. The biology showed antimicrosomial antibodies at 673 UI/l, antithyroglobulin antibodies at 67 UI/l and TSH was stimulated from 1.61 to 3.52 mU/ml by TRH injections. The patient died in 2000 of respiratory failure due to refractory myasthenia gravis.
The daughter of the previous patient, a 34-year-old woman, was first admitted in 1998 with symptoms of anemia. Her past medical history was unremarkable. Blood counts at entry were: hemoglobin 9.8 g/dl, platelets 261 000/ml, white blood cells 6 840/ml with 18% blasts and 5% PMN, LDH 835 UI/l. A bone marrow examination revealed AML 4 Eo with a blast count of 42%. Cytogenetics showed trisomy 8 and t(16;17)(p11;q11) in 95% of the mitoses. The molecular biology was positive for chromosome 16 inversion and negative for AML/ETO rearrangement. The patient received one course of induction chemotherapy (Mitoxantrone, Cytarabine, Etoposide) and achieved a complete remission. Peripheral blood stem cells were collected after consolidation (Cytarabine, Mitoxantrone) and reinfused after a conditioning regimen of total body irradiation, Cytarabine and Cyclophosphamide. The post-transplant course was uneventful. At 2 years after the transplant, she developed hyperthyroidism with TSH o0.01 mU/ml, free T3 5.5 pg/ml, free T4 9.8 pg/ml, high levels of thyrotropin receptor antibodies, TBII increased to 65% and elevation of thyroglobulin to 119.8 ng/ml. She was successfully treated with propylthiouracyl, two doses of radioactive iodine and corticosteroids because of exophthalmia. She is now well on substitutive thyroid hormone therapy.
We consider that the first patient has a 'nonclassic' APS II with Hashimoto's disease, myasthenia gravis and autoimmune myositis. We cannot affirm that he suffers from primary hypogonadism because it can be consecutive to chemotherapy toxicity. On the other hand, his daughter has an AITD with Grave's disease and an autoimmune opthalmopathy, suggesting that a susceptibility to the development of the polyendocrine syndrome, rather than a specific illness, was inherited.
The association of APS II with part of the extended HLA haplotype A1, B8, DR3, DQA1 0501, DQB1 0501 was described more than two decades ago. 1 Our patients do not present this haplotype that is well known to be associated with susceptibility genes for autoimmune disorders. Interestingly, trisomy 8 was found in case number 2. The thyroglobulin (Tg) gene, localized at 8q24, appears to be a major susceptibility gene for AITD. Alterations in Tg could explain interactions between genetic and environmental factors in the etiology of AITD. 2 The incidence of AML is 2/100 000 inhabitants per year. The cause of AML is unknown. Several factors may operate to produce the disease, such as irradiation, chemicals, viruses, predisposing hematological diseases and hereditary factors. An inherited suscep-tibility to leukemia has been inferred from the incidence of disease observed in certain high-risk families, its association with specific hereditable syndromes and the high frequency of concordant leukemia in monozygous twins. A familial history of leukemia in first-degree relatives increases the risk of leukemia by approximately three-to five-fold. 3 When considering the possibility of two coincident sporadic cases of AML in one family, the calculated probability is less than 4/10 9 . Given this extremely low probability, we can consider our case as familial. The literature reports 16 families in which more than one individual developed AML. It appears that different AML subtypes occur within the same family, suggesting that the putative responsible gene may operate at a primitive step in myeloid differentiation. Chromosomal abnormalities are different for nearly each family, with a predominance of monosomy 7, linkage to 21q22.1-22.2, linkage to 16q22 and loss of the long arm of chromosome 5. Case number 2 also had chromosome 16 inversion with AML4 Eo. But these events do not seem to be implicated in the familial predisposition to leukemia, because case 1 had an AML M2 and chromosome 16 inversion is typically associated with M4 subtype. This suggests that chromosome 16 inversion probably acts later in the development of leukemia.
A retrospective review of adult patients with acute leukemia documented thyroid diseases in 3% of the patients. This is a threefold increase in overall incidence compared to the general population. 4 The association of APS II with leukemia has been described in two cases. De Rosa et al 5 described a patient with ALL, APS II and primary empty sella, and suggested that HLA A1, B8 and DR3 played an etiological role in ALL and in APS II. Erglas et al 6 described the association of large granular lymphocyte leukemia and APS II.
In conclusion, familial leukemia is extremely rare. We report here the unique association of both familial AML and APS II in a father and his daughter. Autoimmune diseases presented 21 and 3 years after remission of AML, respectively, suggesting an indirect link between active AML and endocrine autoimmune disease. Owing to the fact that the association of both hematological and autoimmune diseases is extremely improbable, we suggest that a genetic predisposition to both entities exists. Chromosome 8 could be a potential carrier of the implicated gene, but further studies using linkage analysis in APS affected families are needed to confirm it. Mantle cell lymphoma (MCL) is an aggressive B-cell lymphoma that cannot be cured despite aggressive therapy, including autologous stem cell transplantation. Thalidomide is an immunomodulatory drug with numerous properties that has proven effective in relapsed multiple myeloma and, to a lesser extent, in other hematological diseases, such as myelodysplastic syndromes and myeloproliferative disorders. We report two cases of relapsed refractory MCL successfully treated with thalidomide. The first patient is a 70-year-old man, who presented in 1995 with stage IV MCL. He was treated according to the current protocol at our institution, as reported elsewhere. 1 He received CHOP Â four cycles with only a partial response (PR), followed by highdose cytarabine-based chemotherapy (DHAP), and consolidation with an autologous stem cell transplant utilizing total body irradiation (TBI), melphalan, and cytarabine as the preparative regimen. A complete response (CR) was obtained. The patient relapsed 40 months later, presenting with diffuse peripheral and abdominal lymphadenopathy, splenomegaly, bone marrow and peripheral blood involvement, and a lactate dehydrogenase (LDH) level twice the normal. As salvage chemotherapy, the patient received concurrent cytarabine (2 g/m /l) and infection. As a consequence, the patient declined further chemotherapy. After 4 months, when the patient's peripheral lymphadenopathy increased, he received a 4-week course of rituximab (375 mg/m 2 per week) without any response. In June 2001, the patient developed worsening pancytopenia and compressive iliac lymphadenopathy and started thalidomide at 200 mg/day, increasing by 100 mg/day every 2 weeks, up to 500 mg/day. Hematopoiesis and lymphadenopathy progressively improved, with the patient becoming transfusion independent within 2 months of beginning thalidomide. By the 4th month, the hemoglobin and platelet levels had reached 12 g/dl and 176 Â 10 9 /l, respectively, with a complete disappearance of peripheral blood atypical lymphocytes and a 50% reduction in the size of the lymphadenopathy. Over the next year, the patient maintained his response on 300 mg/day of thalidomide. Although the patient was tolerating the thalidomide, the dose was decreased to 200 mg/day for 2 weeks each month, to decrease the risk of chronic thalidomide side effects. After 4 months (September 2002), the patient's disease progressed, with reappearance of the pancytopenia and increased lymphadenopathy. A bone marrow examination was not performed. Thalidomide was increased to 200 mg each day in combination with three courses of monthly dexamethasone (40 mg/day Â 4 days), reachieving a partial response. At 19 months since first starting thalidomide, the patient remains alive and with a good partial response.
The second patient is a 56-year-old man, who presented with stage IV MCL, and initially achieved a CR after receiving three cycles of CHOP, followed by three cycles of DHAP in combination with rituximab, and an autologous stem cell transplant utilizing TBI, melphalan, and cytarabine as consolidation. After 2 years (May 2002), the patient relapsed with bone marrow involvement, splenomegaly, an elevated LDH (600 IU/L), and a poor performance status (KPS ¼ 3). He was started on thalidomide 100 mg/day plus dexamethasone (40 mg/day Â 4 days). After 1 month, the patient demonstrated a significant decrease in splenomegaly and the LDH level, but remained pancytopenic. The dose of thalidomide was not increased because of side effects (constipation, fatigue, and paresthesia) and the dexamethasone was stopped. Over the next 5 months, while taking only thalidomide 100 mg/day, the patient demonstrated progressive improvement of his disease, with resolution of the splenomegaly, normalization of the LDH and hemoglobin levels, and significant improvement of his neutrophil and platelet counts (1.0 and 86 Â 10 9 /l, respectively). At last follow-up (March 2003), the patient maintains his response, taking thalidomide 100 mg/day without any severe toxicity.
Since the first and subsequent reports of its efficacy in multiple myeloma, [2] [3] [4] there has been a growing interest in thalidomide as an anticancer therapy. The precise mechanisms responsible for thalidomide's antitumor effect remain unknown. Thalidomide may act directly on tumor cells to induce apoptosis or cell cycle arrest, 5 or indirectly, by acting to inhibit angiogenesis, 6 alter immune cell cytokine secretion, 7 enhance T cell, 8 natural killer cell, 9 and dendritic cell activity, 10 and inhibit NF-kB activity. 11 These two cases represent the first two reports of the therapeutic potential of thalidomide in refractory MCL. Based on these encouraging preliminary results, and the immediate need for improved therapy for the treatment of MCL, prospective phase II trials involving larger groups of patients are warranted. In vitro studies are underway to delineate the mechanism of action of thalidomide in MCL. 
